Latest News & Features
Americas
As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports. 1 June 2018
Americas
It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione. 1 June 2018
Americas
Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more. 1 June 2018
Americas
Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report. 31 May 2018
Americas
Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports. 31 May 2018
Asia
In India, there are two core areas of the antibody patenting field that are unsettled and need correcting, as Archana Shanker and Nupur Maithani of Anand and Anand explain. 31 May 2018
Asia-Pacific
A court has rejected an appeal by the Australian Competition and Consumer Commission, in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power. 31 May 2018
Americas
Takeda and Aurobindo have agreed to dismiss a dispute over Aurobindo’s filing of an Abbreviated New Drug Application (ANDA) for a generic version of Prevacid Solutab (lansoprazole). 31 May 2018
Asia-Pacific
UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases. 31 May 2018
Americas
The US government has required German company Bayer to divest $9 billion worth of business and assets in order to continue with its proposed $66 billion acquisition of US-based Monsanto. 30 May 2018